DeepMind/Google will not broadly release AlphaFold (or equivalent full-capability protein-design tooling) for several years after this December 2020 discussion, due to ethical and control concerns.
“This is why I think they're going to spend years before this sees the light of day”
View on YouTube
Explanation
DeepMind open-sourced AlphaFold2's code and methods in June/July 2021, about seven months after this prediction, and released the AlphaFold Protein Structure Database in partnership with EMBL-EBI soon after, far faster than the predicted multi-year restriction.
For roughly the next 20–30 years after 2020, Google will operate under extensive, formal oversight regimes (governmental and/or internal governance) specifically related to advanced technologies like DeepMind/AlphaFold, analogous to how nuclear research is tightly overseen.
“the reality is that Google for the next 20 or 30 years will have layers and layers of oversight”
View on YouTube
Explanation
No nuclear-research-style formal oversight regime has emerged around Google/DeepMind's protein-folding or broader AI work; if anything, AlphaFold's code and outputs were made openly and freely available to researchers within a year.
By December 2022, at least one non-Google/DeepMind group (academic, corporate, or startup) will have publicly demonstrated a protein-folding model with AlphaFold-comparable accuracy, effectively replicating the AlphaFold result.
“it’s an inevitability that in the next 24 months, someone else will replicate this”
View on YouTube
Explanation
The University of Washington's Baker Lab released RoseTTAFold in July 2021, matching AlphaFold2's accuracy within about 5-10 GDT_TS points, well within the predicted 24-month window.
As advanced biological design tools become widely accessible over the coming decades, the absolute number of malicious actors able to attempt catastrophic bio-attacks will increase substantially, creating a materially higher global bio-risk driven by scale rather than by a change in per-capita malice rate.
“you then have a law of large numbers problem”
View on YouTube
Explanation
This is a decades-scale, open-ended claim about growing bio-risk from broader access to design tools rather than a specific near-term testable event; not enough time has passed and no clear resolution point exists to score it definitively.
By around 2050, biodefense will have become one of the most important and sizable global industries, comparable in strategic importance and scale to today’s major defense or healthcare sectors.
“I think biodefense 30 years from now is going to be so important.”
View on YouTube
Explanation
The predicted 2050 timeframe is still roughly 24 years away as of 2026, so this cannot yet be resolved.
Between approximately 2050 and 2100, biodefense will emerge as one of the largest global industries by economic size and strategic priority, comparable to or exceeding current major sectors such as conventional defense, energy, or information technology.
“I think biodefense is going to become probably one of the biggest industries on planet Earth, starting in the latter half of this century”
View on YouTube
Explanation
The predicted 2050-2100 window has not yet begun to be testable as of 2026.
By December 2021, multiple startups will be founded that claim to replicate or closely emulate AlphaFold-like protein-folding techniques for use in drug discovery; and between roughly December 2021 and June 2022 (12–18 months from this Dec 2020 episode), on the order of dozens (around 50) of such novel protein-design/protein-focused startups will receive venture funding.
“I think we’re within within one year, JCal, of a lot of startups replicating this AlphaFold, uh, technique and then using that to go do drug discovery. And you'll see 50 startups getting funded 12 to 18 months from now based on some novel protein idea.”
View on YouTube
Explanation
AI-driven protein design and drug discovery saw a major funding boom in 2021-2022, with numerous new startups (e.g., Generate Biomedicines, DeepMind's own spinout Isomorphic Labs, and others building on AlphaFold-style techniques) raising significant venture capital within the predicted window.
If Rudy Giuliani continues prominently advancing election-fraud allegations through the Georgia Senate runoff period (through January 5, 2021), Republican candidates’ chances in the two Georgia runoff elections will be materially harmed compared to a scenario in which he exits the stage quickly.
“the longer that Rudy stays on the stage making these crazy, wild allegations, the worse it gets for Republicans.”
View on YouTube
Explanation
Rudy Giuliani continued prominently pushing election-fraud claims through the Georgia runoff period, and this was widely cited by analysts as a factor that depressed Republican turnout and enthusiasm, contributing to Democrats winning both Georgia Senate seats on January 5, 2021.
In the January 5, 2021 Georgia runoff elections, there is a high likelihood that Democrats will win both contested U.S. Senate seats.
“there is a very good chance that these guys are going to win these two Senate seats”
View on YouTube
Explanation
Democrats Jon Ossoff and Raphael Warnock won both Georgia Senate runoff races on January 5, 2021, exactly as predicted.
Before the January 5, 2021 Georgia runoff elections, leading congressional Republicans will publicly move to curtail or repudiate Rudy Giuliani’s post-election legal and media efforts, effectively pushing him off center stage.
“I think it’s coming, it’s coming.”
View on YouTube
Explanation
Congressional Republican leadership did not move to curtail or repudiate Giuliani before the January 5, 2021 runoffs; he remained a prominent, largely unchecked voice through that period and spoke at the January 6, 2021 rally that preceded the Capitol riot.
In the 2022 U.S. midterm elections (two years from this Dec 2020 recording), Republicans will win back the majority in the House of Representatives and Nancy Pelosi will cease to be Speaker as a result.
“They did win the they did... The Republicans won like 10 or 12 seats in the House. They've almost got the majority back in the House. They almost certainly will win back the House and retire Nancy Pelosi in two years during the midterm election. I'll put money on that right now.”
View on YouTube
Explanation
Republicans won a narrow House majority in the 2022 midterm elections, and Nancy Pelosi stepped down from House Democratic leadership, with Kevin McCarthy becoming Speaker in January 2023.
Between roughly 2020 and 2040, there will be approximately $30 trillion of intergenerational wealth transfer in the United States.
“And we are about to go through over the next 20 years, $30 trillion of wealth transfer.”
View on YouTube
Explanation
The predicted 2020-2040 window has not yet closed as of 2026; mainstream wealth-transfer estimates from firms like Cerulli Associates and Accenture are broadly in a similar order of magnitude to the $30 trillion figure cited (with some estimates running considerably higher over longer windows), but the claim can't be conclusively scored until the window ends.
The broad population (in context, largely the U.S. and other developed countries) will end up needing and receiving vaccines for COVID-19, and these vaccines will be produced by for‑profit pharmaceutical companies that fund their R&D from prior drug profits.
“And we are all going to need a vaccine. These are all coming from for profit companies that thrived on top of R&D.”
View on YouTube
Explanation
COVID-19 vaccines were indeed developed and distributed by for-profit pharmaceutical companies (Pfizer, Moderna, Johnson & Johnson, AstraZeneca) funded substantially by prior R&D and profits, and were needed and taken by the broad population.
Sometime during calendar year 2021, the All-In podcast hosts will launch some mechanism (e.g., via The Syndicate) that allows podcast listeners to co‑invest alongside them in at least one deal.
“Yes we are. We're going to figure out how to do something. We're going to do something to let the people who listen invest alongside us. We're going to figure it out in 2021 at some point.”
View on YouTube
Explanation
No public record could be found confirming or denying a specific 2021 launch of a formal listener co-investment mechanism tied to the All-In podcast (distinct from Jason Calacanis's pre-existing, separate angel syndicate on Syndicate.com); the claim can't be cleanly verified either way.